|
Christopher K. Mirabelli |
|
| Graduation date from Fredonia: | 1977 |
| Major(s) while at Fredonia: |
Biology |
| Other Education | PhD Molecular Pharmacology from Baylor College of Medicine in Houston, Texas. |
| Present professional positions | |
| Managing Director: |
Healthcare Ventures, LLC. 55 Cambridge Parkway, Suite 102, Cambridge, Massachusetts 02142-1234 Office Phone/Fax: 617-252-4346/ 617-252-4342 |
| Past professional positions Positions (academic) |
|
| 1993 -1999 | Chairman of the board and Chief Executive Officer of LeukoSite, Inc. |
| 1999 - 2006 |
Dr. Mirabelli presided over the integration of LeukoSite into Millennium as President of Pharmaceutical R&D and a member of the Company’s Board of Directors until mid-2000. |
| 1989 - 1993 |
Dr. Mirabelli was a founder of Isis Pharmaceuticals, Inc., where he served in a number of senior research and development positions |
| 1981 - 1988 | Director of the Department of Molecular Pharmacology, SmithKline and French Laboratories R&D Division |
| Professional affiliation(s), e.g. Boards, National Committees, etc. | |
|
Board of Directors:
Board of Advisors: |
Anchor Therapeutics, Inc., Anexon, Inc., DecImmune Therapeutics, Inc., Galleon Pharmaceuticals, Inc., Proteostasis Therapeutics, Synovex Corporation, Theraclone Corporation and Trevena, Inc. Harvard Medical School Accelerator Fund |
| Brief bio Chris Mirabelli joined HealthCare Ventures as a Managing Director in 2000. Dr. Mirabelli was chairman of the board and chief executive officer of LeukoSite, Inc. from 1993 through 1999, a company in which HealthCare Ventures was the lead investor. Dr. Mirabelli was a co-founder of Isis Pharmaceuticals and served with SmithKline and French Laboratories R&D Division. Dr. Mirabelli received his Doctorate degree in molecular pharmacology from Baylor College of Medicine.
|
|
